No US market Insmed to file in Europe and Health Canada only
Now that shareholders understand the lie of getting US physicians and insurance companies to cover Arikace,read the words of the CEO."We are preparing for regulatory filings with the EMA and Health Canada, which we expect to make during the first half of 2014,” said Will Lewis, President and Chief Executive Officer of Insmed.
The podhaler is and will remain the #1 CF treatment solution in the U.S.
revenues from the EU and Canada will be less than half of the profits Novartis is reaping in the US The richest market and the most envious market worldwide, the US health system pays out the most by far.